Kaleido Stock Financials

KLDO -  USA Stock  

USD 2.10  0.06  2.78%

Understanding current and past Kaleido Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kaleido Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Kaleido Biosciences' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Kaleido Biosciences' financials over time to get the whole picture.
Kaleido Biosciences Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 88.34 Million. Average Equity is expected to rise to about 43.8 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (74.8 M).
We recommend to make use of analysis of Kaleido Biosciences fundamentals to see if markets are presently mispricing the entity. We were able to break down thirty-three available fundamentals for Kaleido Biosciences, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Kaleido Biosciences financials, including its revenue, cash flow from operations, current liabilities, as well as the relationship between the cash per share and market capitalization . Please also check out Kaleido Biosciences price to book to check the company can sustain itself down the road. Use Kaleido Biosciences to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Kaleido Biosciences to be traded at $2.02 in 90 days.

Kaleido Fundamentals 

 
Refresh
With this module, you can analyze Kaleido financials for your investing period. You should be able to track the changes in Kaleido Biosciences individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Kaleido Biosciences is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Kaleido Biosciences includes many different criteria found on its balance sheet. For example, investors should never minimize Kaleido Biosciences' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Kaleido Biosciences' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Kaleido Biosciences.

Kaleido Biosciences Cash

Chance Of Financial Distress
Over 81
Kaleido Biosciences has more than 81 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Kaleido Biosciences stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Kaleido Biosciences' official financial statements usually reflect Kaleido Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kaleido Biosciences. For example, before you start analyzing numbers published by Kaleido accountants, it's critical to develop an understanding of what Kaleido Biosciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kaleido Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kaleido Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kaleido Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kaleido Biosciences. Please utilize our Beneish M Score to check the likelihood of Kaleido Biosciences' management to manipulate its earnings.

Kaleido Biosciences Company Summary

Kaleido Biosciences competes with Amicus Therapeutics, and Brickell Biotech. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP483347100
LocationMassachusetts; U.S.A
Business Address65 Hayden Avenue
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitekaleido.com
Phone617 674 9000
CurrencyUSD - US Dollar
You should never invest in Kaleido Biosciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kaleido Stock, because this is throwing your money away. Analyzing the key information contained in Kaleido Biosciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Kaleido Biosciences Key Financial Ratios

Generally speaking, Kaleido Biosciences' financial ratios allow both analysts and investors to convert raw data from Kaleido Biosciences' financial statements into concise, actionable information that can be used to evaluate the performance of Kaleido Biosciences over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kaleido Biosciences reports annually and quarterly.

Kaleido Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kaleido Biosciences's current stock value. Our valuation model uses many indicators to compare Kaleido Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kaleido Biosciences competition to find correlations between indicators driving Kaleido Biosciences's intrinsic value. More Info.
Kaleido Biosciences is rated third overall in beta category among related companies. It is rated second overall in ebitda category among related companies . Kaleido Biosciences Earnings Before Interest Taxes and Depreciation Amortization EBITDA are quite stable at the moment as compared to the past year. The company's current value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is estimated at (74.77 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Kaleido Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kaleido Biosciences' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kaleido Biosciences' earnings, one of the primary drivers of an investment's value.

Kaleido Biosciences Systematic Risk

Kaleido Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kaleido Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Kaleido Biosciences correlated with the market. If Beta is less than 0 Kaleido Biosciences generally moves in the opposite direction as compared to the market. If Kaleido Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kaleido Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kaleido Biosciences is generally in the same direction as the market. If Beta > 1 Kaleido Biosciences moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Kaleido Biosciences Financials

What exactly are Kaleido Biosciences Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Kaleido Biosciences' income statement, its balance sheet, and the statement of cash flows. Potential Kaleido Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Current Assets73.28 M48.72 M56.03 M62.31 M
Total Assets82.31 M59.34 M68.25 M73.22 M
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Kaleido Biosciences is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Kaleido grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Kaleido Biosciences January 24, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Kaleido Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kaleido Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kaleido Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Kaleido Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kaleido Biosciences's daily price indicators and compare them against related drivers.
Information Ratio(0.21)
Maximum Drawdown21.54
Value At Risk(8.74)
Potential Upside5.19
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.